Zacks Research Upgrades UCB (OTCMKTS:UCBJY) to Hold

UCB (OTCMKTS:UCBJY) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

A number of other equities research analysts also recently issued reports on the company. Barclays downgraded UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Jefferies Financial Group raised UCB to a “moderate sell” rating in a research note on Monday, June 22nd. Two research analysts have rated the stock with a Strong Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, UCB has a consensus rating of “Moderate Buy”.

UCB Stock Down 1.2%

Shares of OTCMKTS UCBJY opened at $144.63 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04. The firm has a fifty day moving average of $143.65 and a 200-day moving average of $148.03. UCB has a 52-week low of $98.24 and a 52-week high of $168.76.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.